Prevention of HIV Protease Inhibitor-Induced Dysregulation of Hepatic Lipid Metabolism by Raltegravir via Endoplasmic Reticulum Stress Signaling Pathways

• Published in: The Journal of pharmacology and experimental therapeutics Vol. 334; no. 2; pp. 530 - 539
• Main Authors: Cao, Risheng, Hu, Yiqiao, Wang, Yun, Gurley, Emily C., Studer, Elaine J., Wang, Xuan, Hylemon, Phillip B., Pandak, William M., Sanyal, Arun J., Zhang, Luyong, Zhou, Huiping
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.08.2010; The American Society for Pharmacology and Experimental Therapeutics
• Subjects: Animals; Apoptosis - drug effects; Cells, Cultured; Drug Antagonism; Endoplasmic Reticulum - physiology; Gastrointestinal, Hepatic, Pulmonary, and Renal; Hepatocytes - drug effects; Hepatocytes - metabolism; Hepatocytes - pathology; HIV Integrase Inhibitors - adverse effects; HIV Integrase Inhibitors - pharmacokinetics; HIV Integrase Inhibitors - pharmacology; HIV Protease Inhibitors - adverse effects; Hyperlipidemias - metabolism; Hyperlipidemias - pathology; Hyperlipidemias - prevention & control; Lipid Metabolism - drug effects; Lipid Metabolism - genetics; Liver - drug effects; Liver - metabolism; Lopinavir; Male; Mice; Mice, Inbred C57BL; Pyrimidinones - adverse effects; Pyrrolidinones - adverse effects; Pyrrolidinones - pharmacokinetics; Pyrrolidinones - pharmacology; Raltegravir Potassium; Rats; Ritonavir - adverse effects; Signal Transduction; PBS; ACC; NAFLD; RPA; ABC; SREBP; CPT; XBP; ER; CYP7A1; FITC; ATF; LDL; UPR; RT-PCR; XBP-1s; PI; CHOP; FAS; HAART
• ISSN: 0022-3565; 1521-0103; 1521-0103
• DOI: 10.1124/jpet.110.168484

Hyperlipidemia associated with the HIV protease inhibitor (PI), the major component of highly active antiretroviral treatment (HAART) for HIV infection, has stimulated interest in developing new agents that minimize these side effects in the clinic. HIV integrase inhibitor is a new class of anti-HIV agents. Raltegravir is a first-in-its-class oral integrase inhibitor and has potent inhibitory activity against HIV-1 strains that are resistant to other antiretroviral regimens. Our previous studies have demonstrated that HIV PI-induced endoplasmic reticulum (ER) stress links to dysregulation of lipid metabolism. However, little information is available as to whether raltegravir would have similar effects as the HIV PIs. In this study, we examined the effect of raltegravir on lipid metabolism both in primary rat hepatocytes and in in vivo mouse models, and we further determined whether the combination of raltegravir with existing HIV PIs would potentially exacerbate or prevent the previously observed development of dyslipidemia. The results indicated that raltegravir did not induce ER stress or disrupt lipid metabolism either in vitro or in vivo. However, HIV PI-induced ER stress and lipid accumulation were significantly inhibited by raltegravir both in in vitro primary rat hepatocytes and in in vivo mouse liver. High-performance liquid chromatography analysis further demonstrated that raltegravir did not affect the uptake and metabolism of HIV PIs in hepatocytes. Thus, raltegravir has less hepatic toxicity and could prevent HIV PI-induced dysregulation of lipid metabolism by inhibiting ER stress. These results suggest that incorporation of this HIV integrase inhibitor may reduce the side effects associated with current HAART.